Top

Published in:

Open Access 01-12-2012 | Research article

Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients

Authors: Antje Hahnel, Henri Wichmann, Thomas Greither, Matthias Kappler, Peter Würl, Matthias Kotzsch, Helge Taubert, Dirk Vordermark, Matthias Bache

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

It is well known that osteopontin (OPN) plays an important role in tumor progression and that a high OPN expression level in several tumor entities correlates with poor prognosis in cancer patients. However, little is known about the prognostic relevance of the OPN mRNA splice variants.

Methods

We analyzed the mRNA expression levels of different OPN splice variants in tumor tissue of 124 soft tissue sarcoma (STS) patients. Quantitative real-time PCR (qRT-PCR) was used to analyze the mRNA expression level of three OPN splice variants (OPN-a, -b and -c).

Results

The multivariate Cox's proportional hazard regression model revealed that high mRNA expression levels of OPN splice variants are significantly associated with poor prognosis in STS patients (n = 124). Women (n = 68) with high mRNA expression levels of OPN-a and OPN-b have an especially elevated risk of tumor-related death (OPN-a: RR = 3.0, P = 0.01, CI = 1.3-6.8; OPN-b: RR = 3.4, P = 0.01, CI = 1.4-8.2). In particular, we found that high mRNA expression levels of OPN-b and OPN-c correlated with a high risk of tumor-related death in STS patients that received radiotherapy (n = 52; OPN-b: RR = 10.3, P < 0.01, CI = 2.0-53.7; OPN-c: RR = 11.4, P < 0.01, CI = 2.2-59.3).

Conclusion

Our study shows that elevated mRNA expression levels of OPN splice variants are negative prognostic and predictive markers for STS patients. Further studies are needed to clarify the impact of the OPN splice variants on prognosis.

Available only for authorised users

Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006, 16: 79-87. 10.1016/j.tcb.2005.12.005.CrossRefPubMed

Wai PY, Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008, 27: 103-118. 10.1007/s10555-007-9104-9.CrossRefPubMed

Vordermark D, Said HM, Katzer A, Kuhnt T, Hansgen G, Dunst J, Flentje M, Bache M: Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer. 2006, 6: 207-10.1186/1471-2407-6-207.CrossRefPubMedPubMedCentral

Bache M, Kappler M, Said HM, Staab A, Vordermark D: Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem. 2008, 15: 322-338. 10.2174/092986708783497391.CrossRefPubMed

Bramwell VH, Tuck AB, Wilson SM, Stitt LW, Cherian AK, Rorke SC, Al Katib W, Postenka CO, Chambers AF: Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther. 2005, 4: 1336-1341. 10.4161/cbt.4.12.2166.CrossRefPubMed

Gaumann A, Petrow P, Mentzel T, Mayer E, Dahm M, Otto M, Kirkpatrick CJ, Kriegsmann J: Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch. 2001, 439: 668-674.CrossRefPubMed

Sulzbacher I, Birner P, Trieb K, Lang S, Chott A: Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch. 2002, 441: 345-349. 10.1007/s00428-002-0671-4.CrossRefPubMed

Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Wurl P, Taubert H, Vordermark D: Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer. 2010, 10: 132-10.1186/1471-2407-10-132.CrossRefPubMedPubMedCentral

Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest. 1995, 72: 55-63.PubMed

10.

He B, Mirza M, Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006, 25: 2192-2202. 10.1038/sj.onc.1209248.CrossRefPubMed

11.

Blasberg JD, Goparaju CM, Pass HI, Donington JS: Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg. 2010, 139: 1587-1593. 10.1016/j.jtcvs.2009.08.016.CrossRefPubMed

12.

Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW: Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 2009, 35: 1409-1416.PubMed

13.

Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA: Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery. 2009, 146: 232-240. 10.1016/j.surg.2009.03.036.CrossRefPubMedPubMedCentral

14.

Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF: Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008, 122: 889-897. 10.1002/ijc.23204.CrossRefPubMed

15.

Patani N, Jouhra F, Jiang W, Mokbel K: Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res. 2008, 28: 4105-4110.PubMed

16.

Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, Pass HI: Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun. 2009, 382: 514-518. 10.1016/j.bbrc.2009.03.042.CrossRefPubMed

17.

Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, You Y: Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol. 2010, 12: 765-775. 10.1093/neuonc/noq006.CrossRefPubMedPubMedCentral

18.

Tilli TM, Franco V, Robbs B, Wanderley J, Silva F, Mello KD, Viola JP, Weber GF, Gimba ER: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res. 2011, 9: 280-293. 10.1158/1541-7786.MCR-10-0463.CrossRefPubMed

19.

Jahns F, Wilhelm A, Jablonowski N, Mothes H, Radeva M, Wolfert A, Greulich KO, Glei M: Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue. Carcinogenesis. 2011, 32: 913-920. 10.1093/carcin/bgr061.CrossRefPubMedPubMedCentral

20.

Wang HH, Wang XW, Tang CE: Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease. J Cancer Res Ther. 2011, 7: 138-142. 10.4103/0973-1482.82926.CrossRefPubMed

21.

Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007, 26: 6361-6371. 10.1038/sj.onc.1210463.CrossRefPubMed

22.

Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M: Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer. 2010, 102: 731-737. 10.1038/sj.bjc.6605520.CrossRefPubMedPubMedCentral

23.

Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA: Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer. 2006, 6: 237-10.1186/1471-2407-6-237.CrossRefPubMedPubMedCentral

24.

Miyajima J, Hayashi T, Saito K, Iida S, Matsuoka K: The Interaction between female sex hormone receptors and osteopontin in a rat hyperoxaluric model. Kurume Med J. 2010, 57: 73-80. 10.2739/kurumemedj.57.73.CrossRefPubMed

25.

Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005, 6: 757-764. 10.1016/S1470-2045(05)70292-8.CrossRefPubMed

26.

Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M: Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol. 2010, 5: 82-10.1186/1748-717X-5-82.CrossRefPubMedPubMedCentral

27.

Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT: The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One. 2010, 5: e9633-10.1371/journal.pone.0009633.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/131/prepub

Title: Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients
Authors: Antje Hahnel
Henri Wichmann
Thomas Greither
Matthias Kappler
Peter Würl
Matthias Kotzsch
Helge Taubert
Dirk Vordermark
Matthias Bache
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-131

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Biomarkers for antitumor activity of bevacizumab in gastric cancer models

A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C

Body mass index and survival after breast cancer diagnosis in Japanese women

A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design

Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer